This study aims to evaluate the performance of biomarkers and their responsiveness to standard-of-care treatments (Vevye® or Xiidra®), in participants with dry eye disease (DED) compared to healthy volunteers (control participants).
This study aims to characterize longitudinal changes in signs, symptoms, molecular, and imaging markers of the ocular surface to investigate pathological mechanisms and biomarkers (BMs) of DED after treatment with either of two commercially approved therapeutics (Vevye® \[cyclosporine ophthalmic solution\], Xiidra® \[liftegrast ophthalmic solution\]).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
378
Eye Research Foundation
Newport Beach, California, United States
Butchertown Clinical Trials
Louisville, Kentucky, United States
Andover Eye Associates
Andover, Massachusetts, United States
Oculus Research
Garner, North Carolina, United States
Change From Baseline in Corneal Staining as Measured by Sodium Fluorescein
Time frame: Up to Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
CORE Inc.
Shelby, North Carolina, United States
Advancing Vision Research, LLC
Goodlettsville, Tennessee, United States
Total Eyecare, P.A.
Memphis, Tennessee, United States
Piedmont Eye Center
Lynchburg, Virginia, United States